Drug Profile

Mercaptamine bitartrate - Viatris

Alternative Names: Cystagon; Cysteamine - Viatris/Orphan Europe; Cysteamine bitartrate

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mylan
Developer Alphapharm; Mylan; Viatris Inc
Class Mercaptoethylamines; Small molecules; Sulfhydryl compounds
Mechanism of Action Glutathione synthase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Nephropathic cystinosis
New Molecular Entity No

Highest Development Phases

Marketed Nephropathic cystinosis
Discontinued Unspecified

Most Recent Events

09 Apr 2018 Mercaptamine bitartrate licensed to Recordati worldwide
26 Oct 2017 Chemical structure information added
31 Dec 2008 Mercaptamine bitartrate oral is still in phase II/III trials for Undefined indication in European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com